Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Efficacy and Safety of Heated Chinese Herb Medicine Patch Therapy on Chemotherapy-Induced Aplastic Anemia

25 de agosto de 2026 actualizado por: Hung-Rong Yen

The objective of this clinical trial is to establish a treatment for chemotherapy-induced pancytopenia symptoms using heated traditional Chinese medicine (TCM) plasters through a randomized, single-blind clinical trial.

The primary question it aims to answer is whether heated TCM plasters improve chemotherapy-induced pancytopenia symptoms, maintain or increase white blood cells, platelets, and red blood cells, reduce the use of G-CSF and blood transfusions, and enhance cancer patients' quality of life. It also aims to assess if there are any adverse patient reactions to this treatment.

The researchers will compare heated TCM plasters with placebo heated/plaster, placebo TCM plasters, and placebo heated TCM plasters to determine whether the treatment improves chemotherapy-induced pancytopenia symptoms.

Participants will apply the plaster for 1 hour, once daily, 6 days a week for 2 consecutive weeks, totaling 12 applications. Full blood tests (Complete Blood Count, CBC) and white blood cell differential count (DC) will be performed before and after the treatment, and participants will complete the FACT-G cancer treatment-related quality of life scale.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

40

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Taiping District
      • Taichung, Taiping District, Taiwán, 411228
        • Taichung armed forces gereral hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

Patients were eligible if they were:

(i) had a diagnosis of stage I-IV cancer. (ii) be aged 20 years or older. (iii)hematological dysfunction: have experienced a WBC count of <4000/μL or ANC <1500/μL after starting chemotherapy.

(iv) can understand and voluntarily sign the informed consent form t

Exclusion Criteria:

The following conditions disqualify participants from the study:

(i) Patients who are unsuitable for moxibustion, including those with wounds at the moxibustion site.

(ii)Individuals who refuse to sign the informed consent form. (iii) Minors, pregnant women, individuals with mental illnesses, those at risk of harm, or vulnerable groups.

(iv)Leukemia patients, as the disease itself affects blood cell changes. (v) Those who have used leukopoietic agents or received blood transfusions within the past month.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador falso: Control group (sham heated TCM plaster group)
No heat source, no TCM plaster group
The same acupuncture points and frequency are used, but instead of the medicinal cake, 5g of flour colored with caramel dye is applied. An unlit moxa column is placed in a moxibustion box to serve as a placebo heat source.
Experimental: Experimental group (Heated TCM plaster group)
Heat source + TCM plaster group
Each time, 5g of the medicinal powder is combined with 7g of tap water and applied to gauze to form a medicinal cake. The researcher then places it on the Shenque point (International acupuncture point code: RN8). Additionally, a 3g moxa column with a 80:1 moxa wool ratio is ignited and placed in a moxibustion box to generate heat, which is layered over the medicinal cake for 1 hour. The treatment is applied once a day, 6 days a week, for 2 consecutive weeks, totaling 12 sessions.
Comparador de placebos: Heat source without TCM plaster group
heat source, no TCM plaster group
Only 3g of moxa wool (80:1 ratio) is ignited and placed in a moxibustion box to generate heat. The researcher directly applies it to the Shenque point for 1 hour, once a day, 6 days a week for 2 consecutive weeks, totaling 12 sessions. (If the participant feels it's too hot, they can either move the moxa wool around the Shenque point themselves or ask the researcher to do so to avoid burns.)
Comparador de placebos: No heat source with TCM plaster group
no heat source, but TCM plaster group
Only a TCM medicinal cake is applied to the Shenque point, with no heat source or moxibustion box used.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of participants with abnormal blood tests results
Periodo de tiempo: Before the intervention (baseline, Day 1) and within 3 days after completion of the 12 intervention sessions(2 weeks).
A complete blood count (CBC) and differential count (DC) will be performed by the hospital's Department of Laboratory Medicine. A 3 mL blood sample will be collected before and after the intervention, for a total of two blood draws. The test items are as follows:
Before the intervention (baseline, Day 1) and within 3 days after completion of the 12 intervention sessions(2 weeks).

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
"Traditional Chinese Medicine Constitution Questionnaire"
Periodo de tiempo: Before the intervention (baseline, Day 1)
Before the intervention (baseline, Day 1)
"FACT-G Quality of Life Questionnaire for Cancer Patients (Version 4)"
Periodo de tiempo: Before the intervention (baseline, Day 1) and after completion of the 12 intervention sessions (2 weeks)
The Functional Assessment of Cancer Therapy-General Questionnaire(FACT-G)comprises 27 questions that assess four primary dimensions of QOL: physical (PWB; 7 items), social and family (SFWB; 7 items), emotional (EWB; 6 items), and functional well-being (FWB; 7 items). It uses 5-point Likert-type response categories ranging from 0 = 'not at all' to 4 = 'very much'. The total FACT-G score is the summation of the 4 subscale scores and ranges from 0 to 108. The higher scores in FACT-G mean a better or worse outcome.
Before the intervention (baseline, Day 1) and after completion of the 12 intervention sessions (2 weeks)
the number of G-CSF
Periodo de tiempo: the number of G-CSF used during the 12 intervention sessions period (at the end of this cycle, the cycle is 14 days).
the number of G-CSF used during the 12 intervention sessions period (at the end of this cycle, the cycle is 14 days).
the number of blood transfusions
Periodo de tiempo: the number of blood transfusions used during the 12 intervention sessions period (at the end of this cycle, the cycle is 14 days).
the number of blood transfusions used during the 12 intervention sessions period (at the end of this cycle, the cycle is 14 days).

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

25 de junio de 2025

Finalización primaria (Actual)

8 de julio de 2025

Finalización del estudio (Actual)

4 de febrero de 2026

Fechas de registro del estudio

Enviado por primera vez

20 de junio de 2025

Primero enviado que cumplió con los criterios de control de calidad

25 de agosto de 2026

Publicado por primera vez (Actual)

27 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

27 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

25 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir